AR108263A1 - Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo - Google Patents

Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Info

Publication number
AR108263A1
AR108263A1 ARP170101111A ARP170101111A AR108263A1 AR 108263 A1 AR108263 A1 AR 108263A1 AR P170101111 A ARP170101111 A AR P170101111A AR P170101111 A ARP170101111 A AR P170101111A AR 108263 A1 AR108263 A1 AR 108263A1
Authority
AR
Argentina
Prior art keywords
general formula
compound
hydroxialquil
triazol
phenyl
Prior art date
Application number
ARP170101111A
Other languages
English (en)
Inventor
Kersten Matthias Gericke
Frank Sormeier
Hans Militzer
- Rubenbauer Philipp Christian
Heiko Schirmer
Chantal Forstner
Thomas Neubauer
Marie-Pierre Collin
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR108263A1 publication Critical patent/AR108263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Un procedimiento que comprende los pasos [C] y [D], en donde [C] es un compuesto de fórmula general (2), en donde R² es C₁₋₄-alquilo, preferentemente es metilo, se hace reaccionar sucesivamente en un primer paso [C-1] en presencia de una base cloruro de ácido de la fórmula general (3) en donde PG es un grupo protector, preferentemente es acetilo, y el producto intermedio resultante se hace reaccionar en un paso subsiguiente [C-2] en presencia de una base con un compuesto de fenilhidrazina de la fórmula general (4), en donde R¹A y R¹B se seleccionan independientemente del grupo que consiste en hidrógeno, flúor, cloro, metilo, monofluorometilo, difluorometilo, trifluorometilo, etilo, metoxi, difluorometoxi y trifluorometoxi, a un compuesto de 1,2,4-triazolilo de la fórmula general (5), en donde PG, R¹A y R¹B son como se ha definido anteriormente, y se hace reaccionar en un paso subsiguiente [D] por escisión del grupo protector PG a un compuesto de la fórmula general (1) en donde R¹A y R¹B son como se ha definido anteriormente.
ARP170101111A 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo AR108263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168163 2016-05-03

Publications (1)

Publication Number Publication Date
AR108263A1 true AR108263A1 (es) 2018-08-01

Family

ID=55910849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170101111A AR108263A1 (es) 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
ARP170101113A AR108265A1 (es) 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101113A AR108265A1 (es) 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos

Country Status (6)

Country Link
US (1) US10815205B2 (es)
EP (1) EP3452470B1 (es)
AR (2) AR108263A1 (es)
TW (1) TW201806943A (es)
UY (1) UY37221A (es)
WO (1) WO2017191107A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700897A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
US11173151B2 (en) 2017-10-24 2021-11-16 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081299A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft AMINE SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
HUE057278T2 (hu) 2017-10-24 2022-04-28 Bayer Ag Szubsztituált tirazol-származékok prodrugjai és ezek alkalmazása
CA3084421A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
KR20220008956A (ko) 2020-07-14 2022-01-24 삼성전자주식회사 반도체 소자
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN107074783B (zh) 2014-11-03 2020-06-05 拜耳制药股份公司 羟烷基取代的苯基三唑衍生物及其用途

Also Published As

Publication number Publication date
TW201806943A (zh) 2018-03-01
UY37221A (es) 2017-11-30
US20190161454A1 (en) 2019-05-30
EP3452470A1 (en) 2019-03-13
US10815205B2 (en) 2020-10-27
WO2017191107A1 (en) 2017-11-09
EP3452470B1 (en) 2020-03-18
AR108265A1 (es) 2018-08-01

Similar Documents

Publication Publication Date Title
AR108263A1 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CR20130102A (es) Imidazopiridazinas sustituidas
PH12016500169A1 (en) Polymorph of syk inhibitors
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20200484A (es) COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574)
UY31612A1 (es) Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica
MX2018014849A (es) Derivados de adenosina para usarse en el tratamiento de cancer.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
MX369642B (es) Sales de dasatinib.
CR9684A (es) Nuevos derivados de la benzoheterocicliletil carboxamida
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
MX2017003238A (es) Metodo para preparar 2'-o-fucosil-lactosa.
MX2017001459A (es) Sintesis de fosforamidatos.
MX337320B (es) Análogos halogenados de agentes anti-fibroticos.
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
PE20190202A1 (es) Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
MX2019001393A (es) 1-hidroximetil-1,2,2,6-tetrametil-ciclohexano y sus derivados y su uso como productos quimicos aromaticos.
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
MX2022004631A (es) Metodos para la preparacion del acido 5-bromo-2-(3-cloropiridin-2- il)-2h-pirazol-3-carboxilico.
MY161067A (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
CO2020008334A2 (es) Derivados de triptófano como endulzantes

Legal Events

Date Code Title Description
FB Suspension of granting procedure